Gilead Sciences Inc. had its stock rating reiterated

Gilead Sciences Inc. had its stock rating reissued by several financial analysis reports.

By Jason Spencer |
Nov 03, 2016

Gilead Sciences Inc. had its stock rating reissued by several financial analysis reports.

Gilead Sciences Inc (NASDAQ: GILD), a biopharmaceutical company, had a "buy" rating before Saturday. Evercore ISI financial analysts issued a report on Saturday that reiterated that rating. As of now, Evercore ISI has a $90 price target on Gilead Sciences Inc. The Evercore ISI price objective has a potential upside of GSI as 23.71 percent from the current price.

Evercore is not the only financial institution to rethink their ranking of Gilead Sciences Inc. As recently as a research report that was released in late July, Piper Jaffray Cos. reduced their price target on GSI from $114 to $108. Piper Jaffray rated GSI as "overweight". Royal Bank of Canda also reduced their price target on GSI from $120 to $105. They set their rating of GSI at "outperform".

Jefferies Group reiterated a "hold" rating of Gilead Sciences Inc. and dropped their price target from $97 to $93. Robert W. Baird reiterated their "outperform" rating of GSIand dropped their price rating from $135 to $122. Credit Suisse Group AG reiterated their "buy" rating and dropped their price target from $120 to $115.

In all, ten issued research reports have Gilead Sciences as a "hold" rating and eighteen have the company at a "buy" rating. Two others have issued "strong buy" ratings to GSI. GSI has a consensus rating of "Buy" and a consensus target price of $103.78. GSI opened at 72.75 on Friday and their 200 day moving average price is $84.45. Their 50 day moving average price is $77.93.

---

Have something to say? Let us know in the comments section or send an email to the author. You can share ideas for stories by contacting us here.

Comments

Comments should take into account that readers may hold different opinions. With that in mind, please make sure comments are respectful, insightful, and remain focused on the article topic.